Hong Kong stocks surged | Ascletis Pharma-B (02137.HK) rose more than 4% and granted exclusive commercial license for new drug BRII-693 in Greater China to Health

According to the Securities Times APP, Tengsheng Boyao-B (02137.HK) rose more than 4%, up 4.24% to HK$1.72 as of the time of writing, with a trading volume of HK$3.6514 million.